Functional proteomic aberrations post-chemotherapy with paclitaxel and carboplatin in patients with advanced ovarian cancer

被引：0
|
作者：
Lee, Sanghoon [1 ]
Zhao, Li [1 ]
Celestino, Joseph [1 ]
Rangel, Kelly M. [1 ]
Hajek, Richard A. [1 ]
Kim, Mark S. [1 ]
Sharafi, Sara E. [1 ]
Liu, Jinsong [1 ]
Fleming, Nicole D. [1 ]
Lu, Karen H. [1 ]
Zhang, Jianhua [1 ]
Futreal, P. Andrew [1 ]
Mills, Gordon B. [2 ]
Westin, Shannon N. [1 ]
Sood, Anil K. [1 ]
Jazaeri, Amir A. [1 ]
Coleman, Robert L. [1 ]
机构：
[1] UT MD Anderson Canc Ctr, Houston, TX USA
[2] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
来源：
CANCER RESEARCH | 2020年 / 80卷 / 16期
关键词：
D O I：
10.1158/1538-7445.AM2020-2941
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2941
引用
收藏
页数：2
相关论文
共 50 条
  • [31] First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer - a new standard of care?
    du Bois, A
    Neijt, JP
    Thigpen, JT
    ANNALS OF ONCOLOGY, 1999, 10 : 35 - 41
  • [32] Improved survival with consolidation chemotherapy after adjuvant paclitaxel and carboplatin in advanced epithelial ovarian cancer
    Shafer, A.
    Ayeni, T. A.
    Deal, A. M.
    Secord, A. Alvarez
    Soper, J. T.
    Havrilesky, L. J.
    Van Le, L.
    Gehrig, P. A.
    GYNECOLOGIC ONCOLOGY, 2009, 112 (02) : S135 - S136
  • [33] Cytokines, GM-CSF and IFNγ administered by priming and post-chemotherapy cycling in recurrent ovarian cancer patients receiving carboplatin
    Apte, SM
    Vadhan-Raj, S
    Cohen, L
    Bassett, RL
    Gordon, IO
    Levenback, CF
    Ramirez, PT
    Gallardo, ST
    Patenia, RS
    Garcia, ME
    Iyer, RB
    Freedman, RS
    JOURNAL OF TRANSLATIONAL MEDICINE, 2006, 4 (1)
  • [34] Cytokines, GM-CSF and IFNγ administered by priming and post-chemotherapy cycling in recurrent ovarian cancer patients receiving carboplatin
    Sachin M Apte
    Saroj Vadhan-Raj
    Lorenzo Cohen
    Roland L Bassett
    Ilyssa O Gordon
    Charles F Levenback
    Pedro T Ramirez
    Stacie T Gallardo
    Rebecca S Patenia
    Michael E Garcia
    Revathy B Iyer
    Ralph S Freedman
    Journal of Translational Medicine, 4
  • [35] Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: Safety and effectiveness
    Miranda, Vanessa da Costa
    de Souza Fede, Angelo Bezerra
    dos Anjos, Carlos Henrique
    da Silva, Juliana Ribeiro
    Sanchez, Fernando Barbosa
    da Silva Bessa, Lyvia Rodrigues
    Carvalho, Jesus de Paula
    Abdo Filho, Elias
    de Freitas, Daniela
    Estevez Diz, Maria del Pilar
    GYNECOLOGIC ONCOLOGY, 2014, 132 (02) : 287 - 291
  • [36] Safety and Efficacy of Weekly Paclitaxel and Cisplatin Chemotherapy for Ovarian Cancer Patients with Hypersensitivity to Carboplatin
    Tate, Shinichi
    Nishikimi, Kyoko
    Matsuoka, Ayumu
    Otsuka, Satoyo
    Shozu, Makio
    CANCERS, 2021, 13 (04) : 1 - 11
  • [37] Cisplatin/paclitaxel vs carboplatin/paclitaxel: Optimizing of treatment in advanced ovarian cancer
    Mobus, V
    Jackisch, C
    Luck, HJ
    Meier, W
    Bauknecht, T
    Costa, S
    Richter, B
    Nitz, U
    duBois, A
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 531 - 531
  • [38] Patients with carboplatin, paclitaxel, and epirubicin combination as first-line chemotherapy in ovarian cancer
    Kristensen, GB
    Havsten, H
    Kaern, J
    Tropé, C
    SEMINARS IN ONCOLOGY, 1999, 26 (01) : 96 - 96
  • [39] Pharmacokinetics of paclitaxel and carboplatin in a hemodialysis patient with advanced ovarian cancer
    Yoshida, H.
    Sumi, T.
    Abe, K.
    Ishiko, O.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2009, 30 (05) : 583 - 585
  • [40] Carboplatin plus paclitaxel scheduling for advanced ovarian cancer Reply
    Pignata, Sandro
    Di Maio, Massimo
    Gallo, Ciro
    Perrone, Francesco
    LANCET ONCOLOGY, 2014, 15 (07): : E250 - E251
12345